Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Angeion/Ela Medical

This article was originally published in The Gray Sheet

Executive Summary

Angeion/Ela Medical: Firms establish a 50-50 joint venture for combined U.S. marketing of cardiac rhythm management products. The product line-up includes Synthelabo subsidiary Ela Medical's Chorus RM, Chorus RM DDD, Opus RM and Opus RM SSI pacemakers and, pending FDA approval, Angeion's Sentinel series implantable cardioverter defibrillators and defibrillator lead systems ("The Gray Sheet" June 23, In Brief). The combined portfolio also will contain ELA's Defender dual chamber ICDs. The joint venture will be headed by Dennis Sellke, CEO, former president and CEO of Clarus Medical Systems. Internationally, the firms' relationship includes marketing of Angeion ICDs under Ela trademarks by Ela's established direct sales and marketing network in Europe and Japan. The agreement includes an equity investment by Synthelabo of $15-30 mil. in Angeion -- including an initial payment of $15 mil. upon closing (which is subject to review by the Federal Trade Commission) -- and an additional $15 mil. upon achievement of certain milestones over the next 18-24 months. In addition "the exercise of warrants issued to Synthelabo as part of this transaction could raise up to an additional $18 mil. for Angeion," Angeion states...

You may also be interested in...



Health And Wellness Trademark Review 1 December, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Ipsen CEO Outlines Strategy For Long-Term Success

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare

Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel